Safety, pharmacokinetics, and pharmacodynamics of 4-hour intravenous infusion of eritoran tetrasodium in healthy Japanese and Caucasian males

Documenti analoghi

• Safety, Pharmacokinetics, Pharmacodynamics, and Plasma Lipoprotein Distribution of Eritoran (E5564) during Continuous Intravenous Infusion into Healthy Volunteers
  di: Rossignol, Daniel P., et al.
  Pubblicazione: (2004)
• Evaluation of eritoran tetrasodium (E5564), a TLR4 antagonist, on the QTc interval in healthy subjects
  di: Nagy, CF, et al.
  Pubblicazione: (2011)
• Eritoran tetrasodium (E5564) Treatment for Sepsis: Review of Preclinical and Clinical Studies
  di: Barochia, Amisha, et al.
  Pubblicazione: (2011)
• Inhibition of Corneal Inflammation by the TLR4 Antagonist Eritoran Tetrasodium (E5564)
  di: Sun, Yan, et al.
  Pubblicazione: (2008)
• Influence of severity of illness on the effects of eritoran tetrasodium (E5564), a TLR4 antagonist, in patients with severe sepsis
  di: Opal, SM, et al.
  Pubblicazione: (2009)